Skip to main content
Caplight Logo









N-Zyme Biomedical

N-Zyme Biomedical

Private
Newark, DelawareHealthcare & Life Scienceshttps://nzymebio.com

Last Round

Series A

Jul 22, 2026

Total Funding Raised

$4.6M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

N-Zyme Biomedical operates in Healthcare & Life Sciences and is based in Newark, Delaware. Its latest recorded funding round was a Series A round in July 2026.

N-Zyme Biomedical is a clinical-stage biotechnology company developing first-in-class therapies targeting pepsin to treat laryngopharyngeal reflux and gastroesophageal reflux disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

N-Zyme Biomedical Comparables

Compare N-Zyme Biomedical with similar companies based on industry and business-model similarity.

N-Zyme Biomedical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ellodi Pharmaceuticals
68%
The Reflux Company
66%
Phathom Pharmaceuticals
66%
Book a demo to see all comparables

For institutional investors. Book with your work email.

N-Zyme Biomedical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 22, 2026
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Franco Vigile

Co-Founder, CEO

Founding Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 76% MoM, reaching 4.8K.

  • Jul 22, 2026

    $5M round completed.

Book a demo to see all signals

For institutional investors. Book with your work email.

N-Zyme Biomedical Filings

Explore SEC and related filing metadata, where available.

N-Zyme Biomedical filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about N-Zyme Biomedical's valuation, stock price, and market status.

Is N-Zyme Biomedical a public or private company?

N-Zyme Biomedical is a private company.

What is the current stock price of N-Zyme Biomedical?

N-Zyme Biomedical is a private company, so its shares have no public market price. Caplight tracks N-Zyme Biomedical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is N-Zyme Biomedical worth (valuation)?

Valuation information for N-Zyme Biomedical is not publicly available.

Can I buy N-Zyme Biomedical stock?

N-Zyme Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was N-Zyme Biomedical's last funding round?

N-Zyme Biomedical's most recent funding round was Series A on July 22, 2026.

Who are the main investors in N-Zyme Biomedical?

Investor information for N-Zyme Biomedical is not publicly disclosed.

Will N-Zyme Biomedical IPO soon?

No public IPO plans have been announced for N-Zyme Biomedical.

How can I track N-Zyme Biomedical secondary market activity?

Caplight tracks bids, offers, and trades in N-Zyme Biomedical's shares on secondary markets.

Firmographic Details

HeadquartersNewark, Delaware
Employee Range5
Year Founded2021
Last FundingJul 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?